. The most common known high-penetrance susceptibility gene for familial CMM development is CDKN2A, a tumor suppressor gene on chromosome 9p21 that encodes two distinct proteins: p16 INK4A and p14 ARF by alternative splicing of two separate first exons, 1a and 1b, respectively (Hansson, 2008) .
In several countries, specific founder mutations account for most of the germline CDKN2A alterations. For instance, p.R112_L113insR in Sweden and c.225-243del19 in the Netherlands account for B90% of familial mutations. Italy, Spain, and France share their most common mutation (p.G101W), while p.M53I, c.IVS2-105A4G, p.R24P and p.L32P are the most frequent mutations in Australia and the UK (Goldstein et al., 2006) .
BRAF and NRAS are the most frequently somatically altered oncogenes Accepted article preview online 14 June 2013; published online 18 July 2013 Abbreviation: CMM, cutaneous malignant melanoma in CMM, with BRAF mutations detected in B50% and NRAS mutations in B20% of sporadic CMMs (Lee et al., 2011) . The RAS-RAF-MEK-ERK and the PI3K-Akt pathways are commonly activated in melanomas and occur even in the absence of BRAF and NRAS mutations (Fecher et al., 2008) .
The purpose of this study was to investigate whether inheritance of the high-penetrance susceptibility gene CDKN2A can affect the prevalence of somatic BRAF/NRAS mutations in familial CMM. We also wanted to determine if there is a correlation between the expression of phosphorylated (p)-ERK and phosphorylated (p)-Akt and germline CDKN2A status. The study was performed as a collaborative investigation within the GenoMEL consortium (www.genomel.org).
Formalin-fixed paraffin-embedded primary familial CMMs were collected from eight centers in Europe and Australia. Patient and tumor features are shown in Table 1 . In total, 135 familial CMMs from 128 patients were successfully analyzed for mutations in BRAF and/or NRAS, 89 from patients with germline CDKN2A mutations and 46 from patients without germline CDKN2A mutations. Six patients had multiple primary tumors. For comparison purposes, we also included a control group consisting of 50 primary sporadic CMMs matching the familial cohort (Table 1) . Methods used (Laser capture microdissection, sequencing of BRAF exon 15 and NRAS exon 2 and pERK/pAkt immunohistochemistry) were as previously described (Omholt et al., 2011) . Fisher's exact test, Kruskal-Wallis rank or Mann-Whitney tests was used to test association of BRAF and NRAS mutation with germline CDKN2A status and patient and tumor characteristics. This study was approved by Ethics Review Boards of each participating center.
BRAF and NRAS mutations were identified in 43% and 11% of familial CMMs, respectively (Table 2 ). In no case were BRAF and NRAS mutations found to coexist in the same tumor. There was no significant difference in BRAF and NRAS mutation frequencies between tumors from patients with and without germline CDKN2A alterations (Table 2) . There was also no difference in BRAF mutation frequency between tumors with CDKN2A mutations disrupting both p16 INK4A and p14 ARF and tumors with CDKN2A mutations affecting p16 INK4A only. With respect to different types of germline CDKN2A mutations, BRAF mutations were found in 5 of 8 p.M53I (62%), 11 of 24 p.R112_L113 insR (46%), 3 of 8 p.G101W (37%), and 7 of 20 c.225_243del19 (35%) altered tumors. NRAS mutations were observed in 1 of 8 p.M53I (12%), 3 of 21 p.R112_L113insR (14%), and 2 of 20 c.225_243del19 (10%) altered tumors. No NRAS mutations were detected in eight tumors with the p.G101W mutation.
In six familial patients, more than one primary melanoma was analyzed. In four cases, multiple tumors from the same patient had identical BRAF and NRAS genotypes. However, in one patient with three melanomas all tumors had different BRAF genotypes, and in another patient with two tumors the NRAS genotype differed (Supplementary Table S1 online).
Of 55 familial tumors with BRAF mutations, 51 had the V600E mutation. Other observed BRAF mutations included V600K (n ¼ 3) and one tandem V600E (c.1799TG4AA). One tumor had two different BRAF mutations (V600E and K601E), and another contained a 12 base-pair deletion (c.1802_1813del12) in addition to a V600E change. The identified NRAS mutations included Q61K (n ¼ 8), Q61R (n ¼ 4), Q61L (n ¼ 1), and Q61H (n ¼ 1).
The tumor thickness varied significantly among BRAF mutated (1.0 mm), NRAS mutated (1.4 mm), and BRAF/ NRAS wild-type familial CMMs (0.6 mm; P ¼ 0.004; Supplementary  Table S2 online). Other examined features showed no association with BRAF and NRAS mutation status (Supplementary Table S2 online).
Expression of pERK and pAkt was observed in 65% and 46% of familial CMMs, respectively, but showed no association with CDKN2A mutation status ( Supplementary Table S3 online). Similar frequencies of pERK and pAkt expression were detected in the sporadic cohort ( Supplementary Table  S3 online).
In the sporadic cohort, BRAF mutations were detected in 41% and NRAS mutations were detected in 12%. Thus, the frequency of BRAF and NRAS mutations in sporadic CMMs did not differ significantly from that identified in familial CMMs (Table 2 ). Similar to a trend observed in the familial tumors, age at diagnosis differed significantly among patients with BRAF mutated (43 years), NRAS mutated (58 years), and BRAF/NRAS wild-type sporadic tumors (59 years; P ¼ 0.029).
We have previously analyzed an independent set of 19 familial CMMs with different germline CDKN2A alterations and found a BRAF and NRAS mutation frequency of 37% and 16%, respectively, consistent with the current report (Jovanovic et al., 2010) . Eskandarpour et al. (2003) earlier analyzed an independent set of familial CMMs with the Swedish p.R112_L113insR founder mutation and identified NRAS mutations in 94% (15/16) of the tumors. In the present study, we observed an NRAS mutation rate of 14% in tumors with the p.R112_L113insR mutation. The reason for the discrepancy in NRAS mutation frequency between the studies is unclear, but may be related to chance or the use of different methodologies (single-strand conformation polymorphism vs sequencing).
In conclusion, this is the largest study to date on somatic mutations in familial CMM in individuals with defined germline CDKN2A status. We found that different inherited variants of CDKN2A have no effect on the prevalence of BRAF and NRAS mutations in familial CMM. However, the number of patients recruited to the study was too small to generate sufficient statistical power to definitively assess the association of the somatic BRAF/NRAS mutations and specific germline CDKN2A mutations. Our results revealed that BRAF and NRAS mutation frequencies in familial CMMs were similar to those identified in the sporadic control group and to what has previously been reported in primary sporadic CMMs (Lee et al., 2011) . Thus, our study suggests that although germline CDKN2A mutations in familial CMM predispose to development of melanomas, the somatic genetic alterations are similar to those implicated in sporadic cases. The similarity between familial and sporadic CMMs with respect to somatic mutation pattern implies that novel-targeted drugs towards mutated BRAF and/or MEK are expected to have a similarly important role in familial as in sporadic CMMs. by the European Commission, 6th Framework Programme, contract no. LSHC-CT-2006-018702. The Ministry of Higher Education and Scientific Research/Iraqi-Kurdistan Regional Government is acknowledged for financial support (AZ). The project was also supported by the Swedish Cancer Society. The National Health and Medical Research Council of Australia is acknowledged as the funding source for the Brisbane samples. et al., 2001; Hoefnagel et al., 2005) . In nodal ABC-DLBCL, increased NF-kB activity has a role in its pathogenesis through transcriptional activation of genes involved in cellular survival mechanisms. Previous studies demonstrated that mutations in multiple genes can cause deregulation of NF-kB signaling in nodal ABC-DLBCL (Compagno et al., 2009 ). The genes most frequently affected by these NF-kB-activating genetic aberrations are TNFAIP3 (A20), CD79B, CARD11 (CARMA1), and MYD88, which we investigated in 10 cases of PCLBCL-LT ( Supplementary Table S1 online). TNFAIP3 (A20) is a tumor suppressor gene, downregulating NF-kB signaling by targeting several proteins involved in the activation of this pathway. By quantitative PCR, transcriptional levels of TNFAIP3 varied in our PCLBCL-LT cases ( Supplementary Figure S1 online) , and therefore we investigated potential underlying mechanisms for this variation. Four cases with relatively low mRNA expression levels showed heterozygous deletion of the gene region by highdensity fine-tiling comparative genomic hybridization. Homozygous deletions as observed in 10% of nodal ABC-DLBCL (Compagno et al., 2009) were not found. In cases without deletion of TNFAIP3, but displaying relatively low levels of mRNA, we could not detect epigenetic silencing through promoter hypermethylation, as was encountered in approximately 40% of nodal ABC-DLBCL (Honma et al., 2009) . Possibly, in these cases, reduced mRNA expression was regulated by altered transcription factor 
